Clay Keene offers market access advisory services to pharmaceutical clients, bringing nearly 30 years’ experience in pharmaceutical care, population health, pharmacy benefit and payer economics, and administration of the 340B drug discount program.

Prior to joining Avalere, Clay was a pharmacy benefit consultant with Lockton, focusing on pharmacy benefit design and selection for Employer Groups and health plans. At CVS Health, Clay was responsible for product innovation, which included developing the model and strategy for 340B contract pharmacy services. Clay also served as Vice President of Specialty Strategy and Growth for Maxor Pharmacy Solutions, Vice President of Business Development for ReCept /Omnicell, and Senior Director of Strategy and Contracting for McKesson’s US Oncology and Provider Solutions. In the public sector, Clay was Director for Strategic Planning and Policy in the New York City Mayor’s Office, focusing on healthcare monitoring, prevention, treatment, and care services.

Clay holds a bachelor’s degree in communications from the University of Houston, as well as two master’s degrees from New York University, in social work and healthcare management. 

Authored Content

Ahead of Asembia 2024, Avalere market access experts discuss the potential impacts of IRA provisions, including Part D redesign and Medicare drug price negotiation, on go-to-market and contracting strategy.

Specialty pharmacies are evolving to support the unique distribution requirements of CGTs and the complex patient journey from diagnosis to treatment.